HC Wainwright Comments on MetaVia FY2026 Earnings

MetaVia Inc. (NASDAQ:MTVA – Free Report) – Stock analysts at HC Wainwright issued their FY2026 earnings estimates for shares of MetaVia in a research report issued on Tuesday, November 17th. HC Wainwright analyst A. Ghosh anticipates that the company will earn ($3.07) per share for the year. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for MetaVia’s current full-year earnings is ($2.52) per share. HC Wainwright also issued estimates for MetaVia’s Q4 2026 earnings at ($0.72) EPS, FY2027 earnings at ($3.77) EPS, FY2028 earnings at ($2.28) EPS, FY2029 earnings at ($1.88) EPS and FY2030 earnings at ($1.58) EPS.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of MetaVia in a research report on Monday, October 19th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $20.00.

Read Our Latest Research Report on MetaVia

MetaVia Stock Up 0.9%

Shares of MTVA stock opened at $1.07 on Thursday. MetaVia has a 12 month low of $0.97 and a 12 month high of $13.42. The company has a 50 day simple moving average of $1.41 and a two-hundred day simple moving average of $1.59.

MetaVia (NASDAQ:MTVA – Get Free Report) last posted its quarterly earnings data on Friday, November 13th. The company reported ($0.69) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.04.

MetaVia News Summary

Investors following MTVA have been watching these news items:

  • Positive Sentiment: HC Wainwright maintained a Buy rating and forecasts that annual losses per share will narrow after peaking in 2027, from $3.77 in 2027 to $1.58 by 2030. MetaVia analyst estimates
  • Negative Sentiment: Despite that longer-term improvement, HC Wainwright projects substantial losses in the coming years: $3.07 per share for 2026 and $3.77 for 2027, with a $0.72 loss forecast for Q4 2026. Those estimates point to ongoing cash- and financing-related risk. MetaVia analyst estimates
  • Negative Sentiment: MetaVia received a Nasdaq notice that its stockholders’ equity was below the exchange’s listing requirement. The deficiency creates a compliance risk and may require the company to take steps to regain compliance. MetaVia Nasdaq compliance notice

About MetaVia

(Get Free Report)

MetaVia, Inc. is a clinical-stage biotechnology company focused on developing treatments for cardiometabolic diseases, including obesity, metabolic dysfunction-associated steatohepatitis (MASH) and type 2 diabetes. The company’s pipeline includes DA-1726, an investigational dual GLP-1 and glucagon receptor agonist being studied for obesity, and DA-1241, an investigational GPR119 agonist being developed for MASH and type 2 diabetes. These candidates are experimental and have not been established as approved treatments.

See Also

Earnings History and Estimates for MetaVia (NASDAQ:MTVA)

Receive News & Ratings for MetaVia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetaVia and related companies with MarketBeat.com's FREE daily email newsletter.